Article November 1, 2003

Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone

Stephen R. Marder, MD; Robert Conley, MD; Larry Ereshefsky, PharmD, BCCP, FCCP; John M. Kane, MD; Martin S. Turner, MB, BS

J Clin Psychiatry 2003;64(suppl 16):41-46

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

The availability of a long-acting injectable atypicalantipsychotic may increase compliance with medication regimens in patients with schizophrenia. Currently,long-acting risperidone is the only such agent. It is nowavailable or approved in 33 countries, including Austria,Germany, Mexico, the Netherlands, New Zealand, and the United Kingdom.’ ‹’ ‹